Evidence map›Paper›PMID 41796994›Full record

ArticleJournal of gynecologic oncology2026

PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan.

Wei-Ting Chao, Yu-Wen Sung, Kuan-Ju Huang, Lian-Shung Yeh, Bor-Ching Sheu, Wen-Chun Chang, Shang-Hsuan Peng, Po-Han Lin, Peng-Hui Wang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei-Ting ChaoDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-9234-8853
Yu-Wen SungDepartment of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.ORCID https://orcid.org/0000-0002-8229-7623
Kuan-Ju HuangDepartment of Obstetrics and Gynecology, National Taiwan University Hospital, Yunlin Branch, Douliu, Taiwan.ORCID https://orcid.org/0000-0001-9502-7000
Lian-Shung YehDepartment of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.ORCID https://orcid.org/0000-0003-1262-9749
Bor-Ching SheuDepartment of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0003-1278-6082
Wen-Chun ChangDepartment of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0003-4359-4905
Shang-Hsuan PengDepartment of Oncology, National Taiwan University Hospital, Yunlin Branch, Douliu, Taiwan.ORCID https://orcid.org/0000-0002-5260-9585
Po-Han LinDepartment of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0001-6066-398X
Peng-Hui WangDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-6048-8541

Funding

National Taiwan University Hospital Yunlin Branch 114-S012Taipei Veterans General Hospital V114C-039Taipei Veterans General Hospital V115C-095Taiwan Female Cancer Foundation JGO-25-0259Taiwan National Science and Technology Council, Executive Yuan 110-2314-B-075-016 MY3Taiwan National Science and Technology Council, Executive Yuan 113-2314-B-075-057 MY3
6 · The paper itself

Abstract

objectiveThis study aimed to assess prognosis related to poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy (MT) in newly diagnosed patients with advanced-stage epithelial ovarian cancer (adsOC, primary setting). Additionally, it evaluated the effect on recurrent patients after the front- or second-line PARPi MT (recurrence setting).

methodsThis multicenter retrospective study analyzed adsOC patients undergoing standard of care therapy (cytoreductive surgery and chemotherapy), regardless whether PARPi MT was followed or not from December 2011 to May 2023. The prognostic factors affecting survival outcomes (progression-free survival [PFS] and overall survival [OS]) in primary and recurrence settings were analyzed.

resultsA total of 218 patients were analyzed, including 25% with

conclusionBesides, the best survival occurring in adsOC patients with

Indexed as

Carcinoma, Ovarian EpithelialNeoplasm Recurrence, LocalOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAdultAgedFemaleHumansMaintenance ChemotherapyMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesTaiwanPoly(ADP-ribose) Polymerase InhibitorsBRCA MutationEpithelial Ovarian CancerHomologous Recombination DeficiencyOverall SurvivalPoly(ADP-ribose) Polymerase InhibitorsProgression-Free Survival

Identifiers

PMID41796994
PMCPMC13365737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.